RIG‐I agonists in combination with immune checkpoint inhibitors anti‐PD‐1 and anti‐CTLA‐4 have proven to be effective as a combined therapy for melanoma and AML (Heidegger et al., 2019; Jiang et al., 2019; Ruzicka et al., 2020). This evidence concerns the gene CTLA4 and acute myeloid leukemia.